Navigation Links
Cell Therapeutics Commits to PhRMA's Code on Interactions With Healthcare Professionals
Date:12/22/2009

rop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='79877557';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.celltherapeutics.com/investors_alert">http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive NHL as determined by the FDA (including ODAC), CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


    Media Contact:                       Investors Contact:

    Dan Eramian                          Ed Bell
    T: 206.272.4343                      T: 206.272.4345
    C: 206.854.1200                      Lindsey Jesch Logan
    F: 206.272.4434                      T: 206.272.4347
    E: 
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
2. Dennis Winger Joins Nektar Therapeutics Board of Directors
3. Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors
4. Oxford BioTherapeutics Appoints Michael Moore as Chairman
5. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
6. Cell Therapeutics, Inc. (CTI) to Present at 21st Annual Piper Jaffray Health Care Conference
7. Pearl Therapeutics Appoints Howie Rosen to Board of Directors
8. Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference
9. Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
10. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
11. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Grand Rapids, MI (PRWEB) November 22, 2014 ... the opportunity to simulate the proper management of ... training and test lung devices . Grand Rapids-based, ... Lung” plans to donate two of the respiratory ... $12,000 to $15,000 each. Grand Valley and Muskegon ...
(Date:11/21/2014)... 2014 The science of light and ... with more than 200 primary students in a traveling ... University of Otago Physics Department and funded by an ... members of the university’s OSA/SPIE Student Chapter visited six ... giving children from small, rural schools hands-on lessons in ...
(Date:11/21/2014)... 20, 2014 The November 2014 issue ... an open access journal featuring the following articles:, ... to preserve photoresponsiveness in the retina , ... situ hybridization using chromogenic substrates in zebrafish , ... and protein electrophoresis , Nuclear LC3-positive puncta ...
(Date:11/21/2014)... DIEGO , Nov. 20, 2014 ... has been dosed in its Phase 1 trial ... cisplatin for the treatment of malignant pleural mesothelioma ... Group is conducting clinical trials on ADI-PEG 20, ... agents, for the treatment of several other indications, ...
Breaking Biology Technology:Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... A new,analysis of a landmark weight loss survey ... whites to use unproven dietary,supplements for weight loss. The ... NAASO, The Obesity Society, adds to the growing body,of ... the associated health risks of overweight and obesity is ...
... - New Interactive and Intuitive Tools ... Elsevier, leading publisher of scientific, technical and ... added more,development-partner-tested features on its ScienceDirect platform. ... development partners,involvement has ensured that the new ...
... Cases of Chagas, Disease ... Blood Transfusions, ANAHEIM, Calif., Oct. 20 In the ... first blood-screening test,for Chagas, disease, some 241 blood donations in ... parasite known to cause,this serious and potentially fatal parasitic infection, ...
Cached Biology Technology:New Data Reveal Ethnicity May Play Role in Weight Loss Decisions 2New Data Reveal Ethnicity May Play Role in Weight Loss Decisions 3ScienceDirect Maximizes Research Capabilities, Enhances the Research Process 2ScienceDirect Maximizes Research Capabilities, Enhances the Research Process 3Blood Donations in U.S. Testing Positive for Chagas' Disease 2Blood Donations in U.S. Testing Positive for Chagas' Disease 3Blood Donations in U.S. Testing Positive for Chagas' Disease 4
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
(Date:11/7/2014)... conjunction with the Glendale and ... the Verdugos has announced the " GLENDALE - ... to keep the Verdugo Regional Crime Lab operational after its ... existence, the Lab has processed more than 400 DNA samples, ... "Because our number one priority is the wellbeing of ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... 2012 -- It,s time to economically value the greenhouse gas-trapping ... says mining engineer and geologist Michael Hitch of the University ... mine waste rock for its CO 2 -sequestration potential, or ... be able to offset CO 2 emissions with so-named ...
... GAINESVILLE, Fla. --- The great white shark is one of ... sensationalism, yet its evolutionary history is as misunderstood as its ... relative of megatooth sharks, the white shark,s evolutionary history has ... a study appearing in print and online today in the ...
... microbial hitchhikers we all harbor, the largest dam-removal project ... era of personal genomics are among the winners of ... administered by the American Association for the Advancement of ... professional journalists for distinguished reporting for a general audience. ...
Cached Biology News:Researchers tap into CO2 storage potential of mine waste 2Researchers tap into CO2 storage potential of mine waste 3New ancient shark species gives insight into origin of great white 2New ancient shark species gives insight into origin of great white 3Winners named in 2012 AAAS Kavli Science Journalism Award Competition 2Winners named in 2012 AAAS Kavli Science Journalism Award Competition 3Winners named in 2012 AAAS Kavli Science Journalism Award Competition 4Winners named in 2012 AAAS Kavli Science Journalism Award Competition 5Winners named in 2012 AAAS Kavli Science Journalism Award Competition 6Winners named in 2012 AAAS Kavli Science Journalism Award Competition 7Winners named in 2012 AAAS Kavli Science Journalism Award Competition 8
streptavidin, Alexa Fluor® 750–allophycocyanin conjugate (Alexa Fluor® 750–allophycocyanin streptavidin) *1 mg/mL*...
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
...
Biology Products: